Researchers report in Nature Medicine that a personalised neoantigen vaccine with nivolumab was feasible and acceptably safe in an early ovarian cancer trial.
Disclaimer: We provide an opportunity for paid authorship. However, not every submission is reviewed daily. The owner does not promote or support illegal services such as gambling, casinos, betting, or CBD.
